# Treating stimulant addiction: help when the evidence has limits ## 1. Where the task begins A person may seek help because use is taking up too much of life, because reducing it has become difficult, or because its consequences are getting in the way. They may value the energy, relief or productivity they experience while also wanting more freedom. These experiences deserve a discussion that does not require them to declare their entire experience a mistake. Feeling a benefit does not establish safety; use alone does not establish a diagnosis. Possible poisoning, unconsciousness, seizures or severe breathing difficulties require urgent medical help through the local emergency number. Do not drive yourself. Poisoning symptoms can be delayed, so concern about a dangerous exposure is a reason to obtain timely medical advice. An ordinary consultation booking is insufficient in that situation. [NHS explains this urgency](https://www.nhs.uk/conditions/poisoning/). In other circumstances, a useful first step is to contact a professional who works with stimulant-use problems. The meeting can establish the specific difficulties and the help available. [CDC describes treatment for substance-use disorders](https://www.cdc.gov/overdose-prevention/treatment/index.html) as care tailored to the individual. A person does not need to reach a catastrophe or demonstrate strength of character first. A prescribed medicine, how long it has been taken and an experience of benefit do not, by themselves, establish a disorder either. ## 2. What research can tell us Distinguish cocaine and crack from amphetamine and methamphetamine, and distinguish treatment goals. Remaining in a programme, using less frequently and maintaining continuous abstinence are different outcomes. [The 2024 Cochrane review](https://pubmed.ncbi.nlm.nih.gov/38357958/) associates psychosocial treatment with fewer dropouts. Use outcomes depend on the comparison and follow-up period; much of the research concerns cocaine. [Khalili and colleagues' review](https://link.springer.com/article/10.1007/s11469-024-01379-w) of amphetamine and methamphetamine shows the limits of confident conclusions about treatment outcomes. This does not determine any individual's future. When choosing help, asking what the programme aims to achieve, what it was compared with and how long participants were followed is more useful than seeking one “cure rate.” A group result cannot predict a particular reader's life. Limited confidence in an effect does not make seeking help pointless: it calls for honest expectations and a revised plan when the current one is not working. ## 3. What behavioural work might involve Care should have a clear purpose and content. Ask the professional to explain the proposed meetings, any work between them and how you will assess changes together. Research examines different psychosocial approaches; contingency management has received particular attention. A method's prominence does not describe the quality of a particular programme or its suitability for a particular person. For example, a meeting could explore what happens before use: a difficult conversation, loneliness, work overload or an expectation of relief. It could then look for more accessible ways to get through that particular moment. This is the authors' illustration of a possible task, not a research participant's story or a ready-made therapy protocol. A person can say that an assignment is unclear, unmanageable or disconnected from their life. If a programme offers incentives for agreed outcomes, clarify its rules with its professionals in advance. Relatives should not turn the name of a method into a home system of cash rewards, punishment or secret monitoring. Taking part in therapy gives other people no right to control someone's life. Care should preserve room for questions and disagreement. ## 4. Medicines: researched possibilities and individual decisions [In its 13 January 2021 report, NIH](https://www.nih.gov/news-events/news-releases/combination-treatment-methamphetamine-use-disorder-shows-promise-nih-study) described more frequent trial-defined responses to naltrexone plus bupropion than to placebo among selected adults with methamphetamine-use disorder over 12 weeks. This is a report on a trial, not a promise of lasting recovery. Naming two medicines does not enable someone to assemble a treatment regimen. Suitability, possible interactions, other conditions and monitoring require discussion with a clinician. A decision may address the use disorder itself or another problem needing its own treatment. Naming those purposes clearly helps the person understand why a medicine is being offered and what to expect from it. A medicine's name or the existence of a prescription cannot establish that someone has an addiction. Results for opioid treatment cannot simply be transferred to stimulants either. If someone already takes prescribed medicines, changes need discussion with the prescribing professional; this article does not propose stopping them. [FDA recommends discussing medicine safety and consulting about changes](https://www.fda.gov/consumers/womens-health/use-medicines-wisely). Possible benefits need discussion alongside risks. ## 5. What to discuss at the first meeting Begin with your own task: “I want to reduce use,” “I want to stop,” “I want to understand why I am no longer coping,” or “I need help with the consequences.” Nobody needs to immediately accept someone else's description of their whole life. At the same time, honest information about known use, other substances, prescriptions and difficulties matters to the professional. You can also say when something is unknown or hard to discuss. Ask who conducts the assessment, what experience they have with this problem and how the level of care is chosen. Outpatient meetings, inpatient care or another format need consideration of the person's condition and circumstances. This article provides no home method for deciding which level someone requires. Before booking, ask about age eligibility, language, cost, waiting times and the handling of personal information. At the first meeting, ask how the next contact will happen and what to do if the proposed care is unavailable. These conditions depend on the country and service; American and British material does not establish an entitlement to identical care everywhere. A confirmed booking is not the same as receiving care. ## 6. Maintaining contact between meetings The care plan needs to be workable in ordinary life. Discuss attendance barriers in advance: work, money, transport, unsafe housing, caring responsibilities or language difficulties. Asking for a different format or another service does not mean rejecting recovery. Establish whom to contact, and how, when problems with the plan arise. If use continues or resumes, report what has already happened and review the care with a professional. There is no need to invent another substance experiment, “test control” or conceal changes to produce a pleasing report. When dangerous symptoms appear, follow the urgent medical route described at the start. Recovery may involve work, relationships and an activity the person finds meaningful. Access to help should not depend on already having found a calling, replaced an entire social circle or become perfectly motivated. Sometimes a different contact or more suitable support is needed; this can be discussed before the next crisis. ## 7. Relatives' involvement and their own boundaries An adult can agree to help with finding a service, getting there or having a conversation. Clarify what involvement they want and what information they consent to share. Support does not require secretly checking messages, controlling prescriptions or becoming a constant monitor. A relative can state the limits of their money, time and energy, and seek support for themselves. Children must not monitor use, remind adults about medicines or be responsible for returning an adult to treatment. Violence or threats require separate protection; safety must not wait for someone to agree to change their use. Love and involvement may matter greatly, but they do not make one relative the sole condition or guarantor of another person's recovery. ## 8. Questions for reviewing care Periodically discuss whether contact is being maintained, whether the agreed difficulties have changed and whether the next actions are clear. If a plan is inaccessible, unsafe or unhelpful, ask about revision, further assessment or a different approach. There is no need to wait for the professional to guess that a barrier exists. One good month cannot establish that a problem is resolved forever; one deterioration cannot establish that a person is beyond help. The task is to find care that is sufficiently understandable, accessible and supported, assess its results without humiliation, and adjust it as new information appears. Start by contacting a service or professional and asking directly: “Do you work with these difficulties, and what happens at the first assessment?” ## Appendix: five optional anchors for a conversation These are original preparation questions, not a diagnostic scale or a condition of booking. Use only information you already know, skip any items, and seek help without answering. No deliberate test use or evidence-gathering is required. 1. **My task now.** Which difficulty do I most want help with? 2. **What is already known.** What about use, medicines and consequences am I ready to discuss, and what is still unknown? 3. **Previous help.** What have I already tried, and what helped or hindered participation? 4. **Contact conditions.** Which language, time, money, privacy or safety constraints should I mention? 5. **Next step.** Which contact is actually accessible, and what do I want to ask at the first meeting? ## Sources and limits Content checked 14 October 2026. This article helps prepare a treatment conversation; an individual plan requires assessment. The research below concerns different populations, comparisons and periods. Service information concerns its own countries. - Minozzi and colleagues, [Psychosocial interventions for stimulant use disorder](https://pubmed.ncbi.nlm.nih.gov/38357958/), Cochrane, 15 February 2024. Systematic review; the authors' abstract and metadata were used here, without assessing each included trial. - Khalili and colleagues, [Management of Amphetamine and Methamphetamine Use Disorders](https://link.springer.com/article/10.1007/s11469-024-01379-w), online 20 September 2024, 2025 issue. Network meta-analysis; abstract and selected sections used, with certainty and results depending on the outcome. - NIH, [Combination treatment for methamphetamine use disorder shows promise in NIH study](https://www.nih.gov/news-events/news-releases/combination-treatment-methamphetamine-use-disorder-shows-promise-nih-study), 13 January 2021. Trial news, rather than the research paper itself or information on current medicine access. - CDC, [Treatment of Substance Use Disorders](https://www.cdc.gov/overdose-prevention/treatment/index.html), 25 April 2024. General US care information, not individual indications or evidence for a particular stimulant-treatment medicine. - FDA, [Use Medicines Wisely](https://www.fda.gov/consumers/womens-health/use-medicines-wisely), no explicit page date. Medicine-safety information, not a treatment regimen. - NHS, [Poisoning](https://www.nhs.uk/conditions/poisoning/), page reviewed 12 June 2025. Urgent poisoning advice; contacts and access arrangements need local clarification. ## Tags addiction, stimulants, cocaine, methamphetamine, amphetamine, treatment, psychotherapy, behavioural care, medicines, recovery, relatives, access to care ## About the authors Andrey Zarinsh is the author and founder of United Wisdom. He explores inner transformation, the unity of traditions, intercultural dialogue and contemporary spiritual discipline. Instagram: @andrey.zarinsh. Maria Evilkut is a co-author of United Wisdom. Alongside her research, she seeks to test these ideas in practice and observe how unity and mutual understanding work in real life between people and cultures. Instagram: @ilkutki.